Wednesday, July 21, 2021
The Effects of Vitamin D and COVID-Related Outcomes
As early as November 2020, it was known that there were striking differences in vitamin D status among people who had asymptomatic COVID-19 and those who became severely ill and required intensive care unit (ICU) care. In one study, 32.96 percent of those with asymptomatic cases were vitamin D deficient, compared to 96.82 percent of those who were admitted to the ICU for a severe case.
COVID-19 patients who were deficient in this inexpensive and widely available vitamin had a higher inflammatory response and a greater fatality rate. The Indian study authors recommended “mass administration of vitamin D supplements to populations at risk for COVID-19,” in a study published in Scientific Reports, but this hasn’t happened, at least not in the United States.
As of April 21, the date the U.S. National Institutes of Health (NIH) last updated its COVID-19 treatment guidelines/vitamin D page, the agency stated, “There are insufficient data to recommend either for or against the use of vitamin D for the prevention or treatment of COVID-19.” As you’ll see in the paragraphs that follow, however, the evidence for its use is strong.
Vitamin D Therapy Reduces COVID’s Inflammatory Storm
Vitamin D has multiple actions on the immune system, including enhancing the production of antimicrobial peptides by immune cells, reducing damaging pro-inflammatory cytokines, and promoting the expression of anti-inflammatory cytokines. Cytokines are a group of proteins that your body uses to control inflammation.
If you have an infection, your body will release cytokines to help combat inflammation, but sometimes, it releases more than it should. If the cytokine release spirals out of control, the resulting “cytokine storm” becomes dangerous and is closely tied to sepsis, which may be an important contributor to the death of COVID-19 patients.
Many COVID-19 therapeutics are focused on viral elimination instead of modulating the hyperinflammation often seen in the disease. In fact, uncontrolled immune response has been suggested as a factor in disease severity, making immunomodulation “an attractive potential treatment strategy,” wrote researchers from Singapore in a study published in Nutrition.
In one study published in Scientific Reports in May, researchers investigated the effects of Pulse D therapy—daily high-dose supplementation (60,000 IUs) of vitamin D—for eight to 10 days, in addition to standard therapy, for COVID-19 patients deficient in vitamin D. Vitamin D levels increased significantly in the vitamin D group—from 16 ng/ml to 89 ng/ml—while inflammatory markers significantly decreased, without any side effects.
“Vit.D acts as a smart switch to decrease the Th1 response and pro-inflammatory cytokines while enhancing the production of anti-inflammatory cytokines in cases of immune dysregulation. It is pertinent to note that SARS-CoV-2 virus activates Th1 response and suppresses Th2 response,” they wrote.
They concluded that Pulse D therapy could be safely added to COVID-19 treatment protocols for improved outcomes.
Vitamin D3 Reduces COVID-19 Deaths, ICU Admissions
Another group of researchers in Spain gave vitamin D3 (calcifediol) to patients admitted to the COVID-19 wards of Barcelona’s Hospital del Mar. About half the patients received vitamin D3 in the amount of 21,280 IU on day one plus 10,640 IU on days 3, 7, 15, and 30. Those that received vitamin D fared significantly better, with only 4.5 percent requiring ICU admission compared to 21 percent in the no-vitamin D group.
Vitamin D treatment also significantly reduced mortality, with 4.7 percent of the vitamin D group dying at admission, compared to 15.9 percent in the non-vitamin D group.
“In patients hospitalized with COVID-19, calcifediol treatment significantly reduced ICU admission and mortality,” the researchers wrote in the Journal of Clinical Endocrinology & Metabolism. In response to the findings, British MP David Davis tweeted:
“This is a very important study on vitamin D and Covid-19. Its findings are incredibly clear. An 80 percent reduction in need for ICU and a 60 percent reduction in deaths, simply by giving a very cheap and very safe therapy – calcifediol, or activated vitamin D … The findings of this large and well-conducted study should result in this therapy being administered to every COVID patient in every hospital in the temperate latitudes.”
At one point, the United Kingdom’s National Health Service was offering free vitamin D supplements to people at high risk from COVID-19, but they also state, like the U.S. NIH, “there is currently not enough evidence to support taking vitamin D to prevent or treat COVID-19.”
While their guidance does urge Britons to take a vitamin D supplement between October and March “to keep your bones and muscles healthy,” it only recommends a dose of 400 IUs a day, which is easily 20 times lower than what most people require for general health and optimal immune function.
Dose matters when it comes to COVID-19 recovery. In a randomized clinical trial in Saudi Arabia, researchers compared daily supplementation with either 5,000 IUs or 1,000 IUs oral vitamin D3 among patients with suboptimal vitamin D levels hospitalized for mild to moderate COVID-19. Those in the 5,000 IUs group had a significantly shorter time to recovery for cough and loss of the sense of taste compared to the 1,000 IUs group.
According to the researchers, “The use of 5000 IU vitamin D3 as an adjuvant therapy for COVID-19 patients with suboptimal vitamin D status, even for a short duration, is recommended.”
Hospitalized With COVID-19? Ask for Vitamin D
The evidence continues to grow that treatment with vitamin D leads to significantly better outcomes for people hospitalized with COVID-19. In another example from Spain, hospitalized COVID-19 patients who received vitamin D3 had a mortality rate of 5 percent, compared to 20 percent for those who did not. The researchers explained:
“The protective effect of calcifediol [activated vitamin D] remained significant after adjustment for multiple confounder factors related to severity disease even after selecting those subjects who were older (≥65 years) and had worse oxygen saturation levels at admission (<96 percent).”
Similarly, 76 consecutive patients hospitalized with COVID-19 at Reina Sofia University Hospital in Córdoba, Spain, were randomized to receive either standard care or standard care plus vitamin D3 to rapidly increase vitamin D levels.
Of 50 treated with vitamin D, only one person was admitted to the ICU. Of 26 who were not treated with vitamin D, 13 (50 percent) required admission to the hospital. Researchers noted, “Calcifediol seems to be able to reduce the severity of the disease.”
Further: “Of the patients treated with calcifediol, none died, and all were discharged, without complications. The 13 patients not treated with calcifediol, who were not admitted to the ICU, were discharged. Of the 13 patients admitted to the ICU, two died and the remaining 11 were discharged.”
In a previous review, the researchers explained that vitamin D has favorable effects during both the early viraemic phase of COVID-19 as well as the later hyperinflammatory phase, including for acute respiratory distress syndrome (ARDS), a lung condition that’s common in severe COVID-19 cases, which causes low blood oxygen and fluid buildup in the lungs.
“Based on many preclinical studies and observational data in humans, ARDS may be aggravated by vitamin D deficiency and tapered down by activation of the vitamin D receptor,” they wrote in a study published in The Journal of Steroid Biochemistry and Molecular Biology “Based on a pilot study, oral calcifediol may be the most promising approach.”
Even regular “booster” doses of vitamin D, regardless of baseline levels, appear to be effective in reducing the risk of mortality in people admitted to the hospital with COVID-19, particularly for the elderly.
“This inexpensive and widely available treatment could have positive implications for the management of COVID-19 worldwide, particularly in developing nations,” researchers from the United Kingdom noted.
Low Vitamin D Levels May Increase Death Risk
A systematic review and meta-analysis published in the Journal of Endocrinological Investigation included 13 studies involving 2,933 COVID-19 patients. Vitamin D was a clear winner, with use in COVID-19 patients significantly associated with reduced ICU admission and mortality, along with a reduced risk of adverse outcomes, particularly when given after COVID-19 diagnosis.
When it comes to data to support the use of vitamin D for COVID-19, 87 studies have been performed by 784 scientists. The results show:
53 percent improvement in 28 treatment trials
56 percent improvement in 59 sufficiency studies
63 percent improvement in 16 treatment mortality results
A number of clinical trials are also underway, looking further into the use of vitamin D for COVID-19, including one by Harvard Medical School researchers investigating whether taking daily vitamin D reduces COVID-19 disease severity in those newly diagnosed as well as reducing the risk of infection in household contacts.
‘A Simple and Inexpensive Measure’
Some positive advances have already occurred that could make this potentially lifesaving strategy more widely used. The French National Academy of Medicine issued a statement in May 2020, referring to the use of vitamin D as a “simple and inexpensive measure that is reimbursed by the French National Health Insurance” and detailing the importance of vitamin D for COVID-19.
For COVID-19 patients over 60, they recommend vitamin D testing and if deficiency is found, a bolus dose of 50,000 to 100,000 IU. For anyone under the age of 60 who receives a positive COVID-19 test, they advise taking 800 IUs to 1,000 IUs of vitamin D per day. A vitamin D review paper published in the journal Nutrients in April 2020 recommends higher amounts, however, stating:
“To reduce the risk of infection, it is recommended that people at risk of influenza and/or COVID-19 consider taking 10,000 IU/d of vitamin D3 for a few weeks to rapidly raise 25(OH)D concentrations, followed by 5000 IU/d.
“The goal should be to raise 25(OH)D concentrations above 40-60 ng/mL (100-150 nmol/L). For treatment of people who become infected with COVID-19, higher vitamin D3 doses might be useful.”
The best way to know how much vitamin D you need is to have your levels tested. Data from GrassrootsHealth’s D*Action studies suggest the optimal level for health and disease prevention is between 60 ng/mL and 80 ng/mL, while the cutoff for sufficiency appears to be around 40 ng/mL. In Europe, the measurements you’re looking for are 150 to 200 nmol/L and 100 nmol/L, respectively.
************************************************
Pfizer COVID-19 Vaccine ‘Significantly Less’ Effective Against Delta Variant: Israeli PM
Israel’s top officials are warning that Pfizer’s COVID-19 vaccine is “significantly less” effective at combating the “Delta” variant of the CCP virus.
“We do not know exactly to what degree the vaccine helps, but it is significantly less,” Israeli Prime Minister Naftali Bennett told reporters and cabinet members on July 17. He didn’t elaborate.
The Delta strain, which was first identified in India, now makes up a significant portion of the new COVID-19 cases in the United States and the United Kingdom, according to health officials.
Bennett said that in “Britain, in recent days, we have seen a jump in the number of children who are being hospitalized on a daily basis.”
“This is a development that we are aware of; we are dealing with it rationally and responsibly,” he said.
For months, Israel has relied heavily on administering Pfizer’s COVID-19 vaccine, which uses mRNA technology. Officials have said that more than 5.7 million Israelis have received at least one dose of the vaccine.
Pfizer officials didn’t immediately respond to a request by The Epoch Times for comment about Bennett’s claims.
The Delta variant, meanwhile, has prompted concerns that governments around the world may reimpose strict lockdowns or face-mask requirements in a bid to curb the spread of the virus. For months, officials in the United States and elsewhere promised that mass vaccination campaigns would bring an end to the months-long lockdowns and other COVID-19-related requirements. Now with the rise of Delta infections among vaccinated individuals, it’s unclear what the next steps will be.
COVID-19 is the illness caused by the CCP (Chinese Communist Party) virus.
Lockdowns have been flagged as being ineffective in several recent studies. One conducted by the University of Southern California and the RAND Corp. found that shelter-in-place (SIP) orders didn’t actually save lives.
“We use an event study framework to quantify changes in the number of excess deaths after the implementation of a SIP policy. We find that following the implementation of SIP policies, excess mortality increases,” the researchers wrote in a working paper published by the National Bureau of Economic Research.
In the UK, researchers with several top universities said that about five times as many children died from suicide or related trauma than from COVID-19. They specifically concluded that lockdowns are far more detrimental to children’s health than the virus itself.
According to anonymously sourced reports, Israel is considering a new lockdown due to the variant.
During his remarks on July 17, Bennett said that “our goal is to allow routine life to continue with adjustments to the coronavirus,” although it’s not clear whether that includes lockdowns.
“We all hope to see a slowdown, but the facts at the moment are that there isn’t a slowdown—not here and not around the world,” he said.
******************************************
Also see my other blogs. Main ones below:
http://snorphty.blogspot.com (TONGUE-TIED)
http://edwatch.blogspot.com (EDUCATION WATCH)
http://antigreen.blogspot.com (GREENIE WATCH)
http://pcwatch.blogspot.com (POLITICAL CORRECTNESS WATCH)
http://australian-politics.blogspot.com/ (AUSTRALIAN POLITICS
http://awesternheart.blogspot.com.au/ (THE PSYCHOLOGIST)
https://heofen.blogspot.com/ (MY OTHER BLOGS)
*************************************
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment